Adipokines promote lipotoxicity in human skeletal muscle cells

Archives of Physiology and Biochemistry

Volumn 118, Issue 3, 2012, Pages 92-101

  Taube, Annika ^a   Lambernd, Silja ^a   Van Echten Deckert, Gerhild ^b   Eckardt, Kristin ^a   Eckel, Juergen ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Adipocyte conditioned medium; Exercise; Fatty acid oxidation; Palmitic acid

Indexed keywords

ADIPOCYTOKINE; CD36 ANTIGEN; DIACYLGLYCEROL; FATTY ACID TRANSPORTER; PALMITIC ACID; SLC27A4 PROTEIN, HUMAN;

ADIPOCYTE; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; HUMAN; LIPID PEROXIDATION; METABOLISM; SECRETION (PROCESS); SKELETAL MUSCLE; TRANSPORT AT THE CELLULAR LEVEL;

ADIPOCYTES; ADIPOKINES; ANTIGENS, CD36; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DIGLYCERIDES; FATTY ACID TRANSPORT PROTEINS; HUMANS; LIPID PEROXIDATION; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; PALMITIC ACID;

EID: 84862563469     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2012.688751     Document Type: Article

References (70)

1. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT. (2009). Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 139:1073-81.
2. Aguer C, Foretz M, Lantier L, Hebrard S, Viollet B, Mercier J, Kitzmann M. (2011). Increased FAT/CD36 cycling and lipid accumulation in myotubes derived from obese type 2 diabetic patients. PLoS One 6:e28981.
3. Alvarez-Llamas G, Szalowska E, de Vries MP, Weening D, Landman K, Hoek A, Wolffenbuttel BH, Roelofsen H, Vonk RJ. (2007). Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics 6:589-600.
4. Arner P. (2001). Regional differences in protein production by human adipose tissue. Biochem Soc Trans 29:72-5.
5. Blaak EE, Aggel-Leijssen DP, Wagenmakers AJ, Saris WH, van Baak MA. (2000a). Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes 49:2102-7.
6. Blaak EE, Wagenmakers AJ, Glatz JF, Wolffenbuttel BH, Kemerink GJ, Langenberg CJ, Heidendal GA, Saris WH. (2000b). Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am J Physiol Endocrinol Metab 279:E146-54.
7. Bloomgarden ZT. (2000). Obesity and diabetes. Diabetes Care 23:1584-90.
8. Boden G. (1997). Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10.
9. Bonen A, Parolin ML, Steinberg GR, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Heigenhauser GJ, Dyck DJ. (2004). Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J 18:1144-6.
10. Bosello O, Zamboni M. (2000). Visceral obesity and metabolic syndrome. Obes Rev 1:47-56.
11. Charles MA, Eschwege E, Tibult N, Claude JR, Warnet JM, Rosselin GE, Girard J, Balkau B. (1997). Te role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 40:1101-6.
12. Chavez JA, Summers SA. (2003). Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 419:101-9.
13. Coll T, Eyre E, Rodriguez-Calvo R, Palomer X, Sanchez RM, Merlos M, Laguna JC, Vazquez-Carrera M. 2008. Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells. J Biol Chem 151:1560-69.
14. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. (1981). Te effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000-7.
15. Dietze D, Koenen M, Rohrig K, Horikoshi H, Hauner H, Eckel J. (2002). Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes 51:2369-76.
16. Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J. (2005). Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 54:2003-11.
17. Echten-Deckert G. (2000). Sphingolipid extraction and analysis by thin-layer chromatography. Methods Enzymol 312:64-79.
18. Famulla S, Lamers D, Hartwig S, Passlack W, Horrighs A, Cramer A, Lehr S, Sell H, Eckel J. (2010). Pigment epithelium-derived factor is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int J Obes (Lond) 5:762-72.
19. Fang X, Fetros J, Dadson KE, Xu A, Sweeney G. (2009). Leptin prevents the metabolic effects of adiponectin in L6 myotubes. Diabetologia 52:2190-200.
20. Felber JP, Golay A. (2002). Pathways from obesity to diabetes. Int J Obes Relat Metab Disord 26 (Suppl 2):S39-45.
21. Finegood DT. (2003). Obesity, inflammation and type II diabetes. Int J Obes Relat Metab Disord 27 (Suppl 3):S4-5.
22. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. (2004). Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Tromb Vasc Biol 24:e13-18.
23. Hawley JA. (2002). Adaptations of skeletal muscle to prolonged, intense endurance training. Clin Exp Pharmacol Physiol 29:218-22.
24. Hawley JA. (2009). Molecular responses to strength and endurance training: are they incompatible? Appl Physiol Nutr Metab 34:355-61.
25. Hegarty BD, Cooney GJ, Kraegen EW, Furler SM. (2002). Increased efficiency of fatty acid uptake contributes to lipid accumulation in skeletal muscle of high fat-fed insulin-resistant rats. Diabetes 51:1477-84.
26. Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW. (2003). Te role of intramuscular lipid in insulin resistance. Acta Physiol Scand 178:373-83.
27. Hirabara SM, Curi R, Maechler P. (2010). Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J Cell Physiol 222:187-94.
28. Holloszy JO, Rennie MJ, Hickson RC, Conlee RK, Hagberg JM. (1977). Physiological consequences of the biochemical adaptations to endurance exercise. Ann NY Acad Sci 301:440-50.
29. Hotamisligil GS. (1999). Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 107:119-25.
30. Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, Slentz CA, Tanner CJ, Kuchibhatla M, Houmard JA, Newgard CB, et al. 2009. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 32:1678-83.
31. Jove M, Planavila A, Laguna JC, Vazquez-Carrera M. (2005). Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology 146:3087-95.
32. Junkin KA, Dyck DJ, Mullen KL, Chabowski A, Trush AB. (2009). Resistin acutely impairs insulin-stimulated glucose transport in rodent muscle in the presence, but not absence, of palmitate. Am J Physiol Regul Integr Comp Physiol 296:R944-51.
33. Kelley DE, Simoneau JA. (1994). Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 94:2349-56.
34. Kim J, Choi YS, Lim S, Yea K, Yoon JH, Jun DJ, Ha SH, Kim JW, Kim JH, Suh PG, et al. (2010). Comparative analysis of the secretory proteome of human adipose stromal vascular fraction cells during adipogenesis. Proteomics 10:394-405.
35. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403.
36. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, Dyck JR. (2007a). CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 116:2139-47.
37. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR. (2007b). Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56:2863-71.
38. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, et al. 2008. Mitochondrial overload and incomplete Fatty Acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7:45-56.
39. Lambernd S, Taube A, Schober A, Platzbecker B, Gorgens SW, Schlich R, Jeruschke K, Weiss J, Eckardt K, Eckel J. (2012). Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways. Diabetologia 55:1128-1139.
40. Lee JS, Pinnamaneni SK, Eo SJ, Cho IH, Pyo JH, Kim CK, Sinclair AJ, Febbraio MA, Watt MJ. (2006). Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 100:1467-74.
41. Lehr S, Hartwig S, Lamers D, Famulla S, Mueller S, Hanisch FG, Cuvelier C, Ruige J, Eckardt K, Ouwens DM, et al. (2011). Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics 11(1):M111.010504.
42. Lelliott C, Vidal-Puig AJ. (2004). Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord 28 (Suppl 4):S22-8.
43. Machann J, Haring H, Schick F, Stumvoll M. (2004). Intramyocellular lipids and insulin resistance. Diabetes Obes Metab 6:239-48.
44. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, Delany J P. (2010). Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18:1695-700.
45. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. (2002). Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339-43.
46. Muoio DM. (2010). Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? Biochim Biophys Acta 1801:281-8.
47. Nieto-Vazquez I, Fernandez-Veledo S, De Alvaro C, Lorenzo M. (2008). Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57:3211-21.
48. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, et al. 1999. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48:1600-6.
49. Petersen KF, Shulman GI. (2006). New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy. Obesity (Silver Spring) 14 (Suppl 1):34S-40S.
50. Rajala MW, Scherer PE. (2003). Minireview: Te adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765-73.
51. Randle PJ, Garland PB, Hales CN, Newsholme EA. (1963). Te glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-9.
52. Roden M. (2004). How free fatty acids inhibit glucose utilization in human skeletal muscle. News Physiol Sci 19:92-6.
53. Rosenow A, Arrey TN, Bouwman FG, Noben J P, Wabitsch M, Mariman EC, Karas M, Renes J. (2010). Identification of novel human adipocyte secreted proteins by using SGBS cells. J Proteome Res 9:5389-401.
54. Sabin MA, Stewart CE, Crowne EC, Turner SJ, Hunt LP, Welsh GI, Grohmann MJ, Holly JM, Shield JP. (2007). Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intramyocellular lipid. J Cell Physiol 211:244-52.
55. Schmitz-Peiffer C, Craig DL, Biden TJ. (1999). Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 274:24202-10.
56. Sell H, Dietze-Schroeder D, Eckel J. (2006a). Te adipocyte-myocyte axis in insulin resistance. Trends Endocrinol Metab 17:416-22.
57. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. (2006b). Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 147:2458-67.
58. Sell H, Eckardt K, Taube A, Tews D, Gurgui M, Echten-Deckert G, Eckel J. (2008). Skeletal muscle insulin resistance induced by adipocyte-conditioned medium: underlying mechanisms and reversibility. Am J Physiol Endocrinol Metab 294:E1070-77.
59. Sell H, Eckel J, Dietze-Schroeder D. (2006c). Pathways leading to muscle insulin resistance - the muscle-fat connection. Arch Physiol Biochem 112:105-13.
60. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, Arner P, Eckel J. (2009). Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 58:2731-40.
61. Shulman GI. (2000). Cellular mechanisms of insulin resistance. J Clin Invest 106:171-6.
62. Silverstein RL, Febbraio M. (2009). CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2: re3.
63. Stefanyk LE, Dyck DJ. (2010). Te interaction between adipokines, diet and exercise on muscle insulin sensitivity. Curr Opin Clin Nutr Metab Care 13:255-9.
64. Streit M, Velasco P, Brown L F, Skobe M, Richard L, Riccardi L, Lawler J, Detmar M. (1999). Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155:441-52.
65. Trayhurn P, Beattie JH. (2001). Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60:329-39.
66. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-50.
67. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP. (2007). CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 100:1208-17.
68. Yesner LM, Huh HY, Pearce SF, Silverstein RL. (1996). Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler Tromb Vasc Biol 16:1019-25.
69. Zhong J, Krawczyk SA, Chaerkady R, Huang H, Goel R, Bader JS, Wong GW, Corkey BE, Pandey A. (2010). Temporal profiling of the secretome during adipogenesis in humans. J Proteome Res 9:5228-38.
70. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, et al. (2008). Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134:556-67.